By Marie Rosenthal, MS
The FDA approved plazomicin (Zemdri, Achaogen) for the treatment of adults with complicated urinary tract infections (cUTIs), including pyelonephritis, but rejected a request for a bloodstream infection (BSI) indication.
The aminoglycoside will be given as a once-daily IV infusion. Plazomicin will be indicated for cUTIs, including pyelonephritis, caused by certain Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE) and extended-spectrum